We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Horizon and Transgenomic to Collaborate on Genetic Diagnostic Tests

By Paul Mills
Posted on 05 Feb 2014
Print article
Horizon Discovery (Cambridge, United Kingdom) and Transgenomic (Omaha, NE, USA) have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls. The collaboration will enable Transgenomic to transition from the use of plasmid-derived controls, to Horizon’s Quantitative Molecular Reference Standards for all of its existing assays, and for any new assays developed in the future.

Under the terms of the collaboration agreement, Horizon will provide its renewable, genetically defined Quantitative Molecular Reference Standards in both genomic DNA (gDNA) and formalin fixed paraffin embedded (FFPE) format, via its Horizon Diagnostics division. The Quantitative Molecular Reference Standards will be used as advanced reference standards for Transgenomic’s range of genetic diagnostic tests, and in the development of novel tests and in vitro diagnostic testing kits. The Quantitative Molecular Reference Standard products will be chosen from Horizon Diagnostics’ existing inventory of over 300 products, and Horizon’s GENESIS gene editing platform will also be employed to engineer new lines as needed, to support the development of the new tests and kits.

Paul Morrill, senior vice president of Horizon Diagnostics commented, “Transgenomic operates at the cutting edge of molecular diagnostics and is an ideal partner for Horizon. This collaboration adds to our strong network of world class partners practicing high quality science, and contributes to our goal of advancing personalized medicine and ultimately better patient care. We look forward to working with the Transgenomic team.”

Horizon Diagnostics’ Reference Standard product portfolio comprises validated, engineered cell line derived material, including purified DNA with matched normal and renewable formalin fixed, paraffin embedded samples. The available specimens cover a growing range of oncology biomarkers, manufactured to precise standards including defined allelic frequencies.

Related Links:

Horizon Discovery
Transgenomic


Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Rocking Shaker
HumaRock
New
Urine Strips
11 Parameter Urine Strips

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.